Annual Report

Overview

The report describes Sun Pharma's FY17 consolidated performance, with revenue from operations of INR 315,784.4 million and total income of INR 322,015.9 million. The company expanded its specialty portfolio through products such as BromSite and Odomzo, while tildrakizumab remained filed in the US and Europe awaiting approval. It operated 42 manufacturing facilities across six continents and reported more than 30,000 employees worldwide.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2017
Period: 1 April 2016 – 31 March 2017
Language: English
Pages
File size
Restatement: Disclosed

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services